- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04625530
Perioperative Management in Gynaecological Carcinoma Surgery
February 29, 2024 updated by: University Hospital, Basel, Switzerland
Perioperative Management With Ferric Carboxymaltose and Tranexamic Acid to Reduce Transfusion Rate in Gynaecological Carcinoma Surgery: a Single-blind, Mono-centre, Randomized Trial
This study is to determine the effect of perioperative treatment with intravenous iron and tranexamic acid on the reduction of intraoperative and postoperative RBC transfusions in gynaecological carcinoma patients undergoing abdominal surgery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Radical abdominal surgery often leads to intraoperative bleeding frequently exceeding 1000 ml and approximately 50% of women undergoing this surgery require blood transfusion.
Perioperative blood transfusions have been shown to increase of length of stay, surgical complications, postoperative morbidity and mortality.
There are a few data on the reduction in red blood cell count (RBC) transfusions using perioperative management with intravenous iron and tranexamic acid in women with gynaecological carcinoma surgery.
This study is to determine the effect of perioperative treatment with intravenous iron and tranexamic acid on the reduction of intraoperative and postoperative RBC transfusions in gynaecological carcinoma patients undergoing abdominal surgery.
Study Type
Interventional
Enrollment (Estimated)
126
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gabriela Amstad Bencaiova, Dr. med.
- Phone Number: +41 61 556 59 22
- Email: gabriela.amstad@usb.ch
Study Contact Backup
- Name: Viola Heinzelmann, Prof. Dr. med.
- Email: viola.heinzelmann@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- Department of Obstetrics and Gynaecology, University Hospital Basel
-
Contact:
- Gabriela Amstad Bencaiova, Dr. med.
- Phone Number: +41 61 556 59 22
- Email: gabriela.amstad@usb.ch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- informed consent as documented by signature
- women with gynaecological carcinoma surgery with hemoglobin level between 90-120 g/I and serum ferritin < 100 µg/I (or ferritin index < 3.19) at recruitment
- pregnancy test negative in women younger than 50 years
Exclusion Criteria:
- known hypersensitivity or allergy to ferric carboxymaltose or tranexamic acid
- history or present laboratory signs of bleeding disorders, coagulopathy or thromboembolic events
- history of myocardial infarction within the last year, present unstable angina or severe coronary disease
- increased plasma creatinine levels above 250 µmol/I
- inability to follow the procedures of the study (language problems, severe psychiatric or mental disorders)
- iron overload
- current administration of intravenous iron or previous intravenous iron therapy or blood transfusion within three months
- date of scheduled surgery is outside 28 days after the date of recruitment
- other clinically significant concomitant disease states (e.g., hepatic dysfunction, cardiovascular disease, etc.)
- participation in another study with investigational drug within the 30 days
- enrolment of the investigator, his/her family members, employees and other dependent persons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ferric carboxymaltose
ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
|
Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7.
The colour of ferric carboxymaltose is dark brown.
A single Ferinject administration should not exceed 20 mg iron/kg body weight.
|
Experimental: tranexamic acid
tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
|
Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
The colour of the medicament is transparent.
|
Experimental: ferric carboxymaltose and tranexamic acid
ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered. |
Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
|
No Intervention: no treatment accordingly "current standard of care"
no treatment accordingly "current standard of care" will be given
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of all perioperative (intraoperative and postoperative) administered RBC transfusions
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
number of all perioperative (intraoperative and postoperative) administered RBC transfusions (the absolute rate of RBC transfusions)
|
day of surgery until follow up visit 5 (up to 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in hemoglobin level
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
change in hemoglobin level (g/dl)
|
day of surgery until follow up visit 5 (up to 28 days)
|
rate of transfused women with gynaecological carcinoma during and/or after surgery
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
rate of transfused women with gynaecological carcinoma during and/or after surgery
|
day of surgery until follow up visit 5 (up to 28 days)
|
blood loss measured during surgery (ml)
Time Frame: day of surgery
|
blood loss measured during surgery (ml)
|
day of surgery
|
rate of other blood product transfusions
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
rate of other blood product transfusions (fresh frozen plasma, autologous whole blood)
|
day of surgery until follow up visit 5 (up to 28 days)
|
requirement of additional local or systematic haemostatic therapy (descriptive)
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
requirement of additional local or systematic haemostatic therapy (descriptive)
|
day of surgery until follow up visit 5 (up to 28 days)
|
duration of surgery (minutes)
Time Frame: day of surgery
|
duration of surgery (minutes)
|
day of surgery
|
duration of hospitalisation (days)
Time Frame: from admission to discharge date (up to 56 days)
|
duration of hospitalisation (days)
|
from admission to discharge date (up to 56 days)
|
number of postoperative complications
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
number of postoperative complications: abdominal pain, haemorrhage, reoperation owing to bleeding, wound infection, pulmonary complications, postoperative renal dysfunction, systemic sepsis
|
day of surgery until follow up visit 5 (up to 28 days)
|
postoperative mortality
Time Frame: day of surgery until follow up visit 5 (up to 28 days)
|
postoperative mortality
|
day of surgery until follow up visit 5 (up to 28 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gabriela Amstad Bencaiova, Dr. med., Department of Obstetrics and Gynaecology, University Hospital Basel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2021
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
November 4, 2020
First Submitted That Met QC Criteria
November 10, 2020
First Posted (Actual)
November 12, 2020
Study Record Updates
Last Update Posted (Estimated)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 29, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-01194; sp20Amstad
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data generated by our research will be available as soon as possible, wherever legally and ethically possible.
The data will be made available upon reasonable request.
The deidentified participant data from this study and related documents (study protocol, statistical analysis plan, patient consent form) will be made available upon request.
Researchers may request data to repeat the analyses or use the data for secondary analyses (e. g., systematic review and meta-analysis).
Changes to this plan will be noted in the Data Availability Statement and updated in the registry record (to comply with ICMJE recommendations).
IPD Sharing Time Frame
The data will become available upon reasonable request for one month.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynaecological Carcinoma
-
NHS GrampianRecruitingGynaecological CancerUnited Kingdom
-
Nordic Society of Gynaecological Oncology - Clinical...Australia New Zealand Gynaecological Oncology GroupRecruitingGynaecological CancerNorway
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Fevzi ShakirUnknownHeated Humidified Carbon Dioxide in Gynaecological Laparoscopic SurgeryUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedGynaecological Malignant Tumours With Indication of Pelvic LymphadenectomyFrance
-
Assistance Publique - Hôpitaux de ParisCompletedGYNAECOLOGICAL INFECTIONFrance
-
Institute of Cancer Research, United KingdomAstraZeneca; Cancer Research UKRecruitingGynaecological CancersUnited Kingdom
-
Hospital Universitario 12 de OctubreNot yet recruitingQuality of Life | Sexual Dysfunction | Lymphedema, Lower Limb | Gynaecological Cancer
-
Geoff HallNational Health Service, United KingdomUnknownFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Gynaecological MalignancyUnited Kingdom
-
Royal Marsden NHS Foundation TrustCompletedGynaecological, Urological or Rectal Cancer
Clinical Trials on ferric carboxymaltose
-
Sichuan Huiyu Pharmaceutical Co., LtdThe First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaboratorsCompletedBioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency AnaemiaIron Deficiency | AnaemiaChina
-
Hasselt UniversityZiekenhuis Oost-LimburgCompleted
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
Charite University, Berlin, GermanyUniversity of GöttingenUnknownHeart Failure | Iron-deficiencyGermany
-
St Joseph University, Beirut, LebanonSaint-Joseph University; Vifor PharmaCompletedAnemia, Iron DeficiencyLebanon
-
Istanbul UniversityRecruitingAnemia | Hip Fractures | Complication,PostoperativeTurkey
-
Vifor PharmaTerminatedIron-Deficiency AnemiaFrance, Greece
-
American Regent, Inc.Completed
-
University of ZurichTerminated